Apellis Pharmaceuticals Inc $ 48.17 3.12 (6.93%)
Volume:
771,129
Avg Vol (1m):
603,346
Market Cap $:
3.84 Bil
Enterprise Value $:
3.48 Bil
PE Ratio:
0.00
PB Ratio:
34.45
Financial Strength | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.95 | ||
| Equity-to-Asset | 0.14 | ||
| Debt-to-Equity | 3.52 | ||
| Debt-to-EBITDA | -0.73 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 0.26 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -69626.32 | ||
| Net Margin % | -83027.4 | ||
| ROE % | -347.97 | ||
| ROA % | -84.25 | ||
| ROC (Joel Greenblatt) % | -2948.89 | ||
| 3-Year EBITDA Growth Rate | -47.5 | ||
| 3-Year EPS without NRI Growth Rate | -47.9 |
APLS
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 34.45 | ||
| PS Ratio | 5352.24 | ||
| EV-to-EBIT | -6.8 | ||
| EV-to-EBITDA | -6.81 | ||
| EV-to-Revenue | 5388.79 | ||
| Current Ratio | 9.86 | ||
| Quick Ratio | 9.86 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -52.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 34.41 | ||
| Earnings Yield (Greenblatt) % | -14.72 |